PHARM — Pharming NV Cashflow Statement
0.000.00%
Last trade - 00:00- €677.78m
- €638.43m
- $245.32m
- 54
- 19
- 31
- 24
Annual cashflow statement for Pharming NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | 52.2 | 44.1 | 23.1 | 15 | -12 |
| Depreciation | |||||
| Non-Cash Items | 20.2 | 37.1 | 0.062 | -4.18 | -6.48 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.77 | -5.86 | -4.91 | -1.54 | -14.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 74.4 | 83.6 | 37.8 | 22.5 | -17.3 |
| Capital Expenditures | -25.4 | -15.3 | -16.7 | -1.98 | -1.46 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -2.8 | -0.329 | -4.59 | 7.3 | -128 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Cash from Investing Activities | -28.2 | -15.6 | -21.3 | 5.32 | -129 |
| Financing Cash Flow Items | -29.2 | -25.5 | -29.4 | -3.95 | -4.05 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -63.4 | 60.7 | -27.9 | -4.98 | -1.04 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -15.7 | 131 | -13.2 | 15.4 | -146 |